Antidepressant effects of the muscarinic cholinergic receptor antagonist scopolamine: a review - Wikidata - wikimedia - TriplyDB

Antidepressant effects of the muscarinic cholinergic receptor antagonist scopolamine: a review

Antidepressant effects of the muscarinic cholinergic receptor antagonist scopolamine: a review

http://www.wikidata.org/entity/Q26822244

about

Cognitive remission: a novel objective for the treatment of major depression?Potential of Glutamate-Based Drug Discovery for Next Generation Antidepressants Beyond Monoamines-Novel Targets for Treatment-Resistant Depression: A Comprehensive Review GABA interneurons mediate the rapid antidepressant-like effects of scopolamine.Activities of nicotinic acetylcholine receptors modulate neurotransmission and synaptic architecture Transiently increased glutamate cycling in rat PFC is associated with rapid onset of antidepressant-like effects.How do antidepressants work? New perspectives for refining future treatment approaches.Delineation of molecular pathway activities of the chronic antidepressant treatment response suggests important roles for glutamatergic and ubiquitin-proteasome systems Down-regulation of cholinergic signaling in the habenula induces anhedonia-like behavior.Psychiatric disorders: diagnosis to therapy Pharmacologic treatment of dimensional anxious depression: a review New targets for rapid antidepressant action.HCN Channel Targets for Novel Antidepressant Treatment.Beyond serotonin: newer antidepressants in the future.Expression of the 5-HT1A serotonin receptor in the hippocampus is required for social stress resilience and the antidepressant-like effects induced by the nicotinic partial agonist cytisine Identification and characterization of ML352: a novel, noncompetitive inhibitor of the presynaptic choline transporter.In vitro and in vivo regulation of synaptogenesis by the novel antidepressant spadin.Rodent models of treatment-resistant depression.Ventral tegmental area cholinergic mechanisms mediate behavioral responses in the forced swim test.Gene expression during zombie ant biting behavior reflects the complexity underlying fungal parasitic behavioral manipulation Pretreatment Differences in BOLD Response to Emotional Faces Correlate with Antidepressant Response to Scopolamine α-Melanocyte-stimulating hormone ameliorates ocular surface dysfunctions and lesions in a scopolamine-induced dry eye model via PKA-CREB and MEK-Erk pathways Ventral tegmental area muscarinic receptors modulate depression and anxiety-related behaviors in rats.Multiple Nicotinic Acetylcholine Receptor Subtypes in the Mouse Amygdala Regulate Affective Behaviors and Response to Social Stress.Effect of inhaled drugs on anxiety and depression in patients with chronic obstructive pulmonary disease: a prospective observational study.Cholinergic connectivity: it's implications for psychiatric disorders.Cognition as a therapeutic target in late-life depression: potential for nicotinic therapeutics.Ketamine: NMDA Receptors and Beyond.Molecular and Cellular Mechanisms of Rapid-Acting Antidepressants Ketamine and Scopolamine Leading compounds for the validation of animal models of psychopathology.Positron emission tomography molecular imaging in late-life depression.Five potential therapeutic agents as antidepressants: a brief review and future directions.New perspectives on the involvement of mTOR in depression as well as in the action of antidepressant drugs.Antimuscarinic Use in Females With Overactive Bladder Syndrome Increases the Risk of Depressive Disorder: A 3-Year Follow-up Study.Mood Therapeutics: Novel Pharmacological Approaches for Treating Depression Is Mania the Hypertension of the Mood? Discussion of A Hypothesis.Combination of Nitrous Oxide with Isoflurane or Scopolamine for Treatment-resistant Major Depression.Cholinergic muscarinic receptors: new opportunities to treat psychiatric disorders.Circuit and synaptic mechanisms of repeated stress: Perspectives from differing contexts, duration, and development.Synaptic Loss and the Pathophysiology of PTSD: Implications for Ketamine as a Prototype Novel Therapeutic.

P2860

Q26775386-771EB072-3B6D-4503-9DFD-90367A791F21 Q26782274-A10558C5-9C81-49D4-8D10-370C0B5DF3D9 Q26782993-19A8E85E-8CA1-4D05-BE89-326895D2FCA9 Q27329758-CE97DB1C-AC21-4D6A-919E-5CA671AC0474 Q28083726-71BB1727-7C3C-49D5-846E-60908199F369 Q30841490-E00AF038-F597-4A68-AF27-158B78B60570 Q33619029-3B11B362-C10B-46F8-B369-566461D212A8 Q33635613-F8299680-8299-4C62-822D-AB9ECC37228B Q33678595-F38058D1-D7F1-44B3-A0CE-FBC187756D98 Q33922884-E145D87B-F27E-41D7-9454-23B056D91C84 Q34331887-86AF45B5-B717-43E2-B027-7CE8514DEC7A Q34507177-9E505D79-DD16-4837-9BBC-C87CDE52A6D5 Q34557298-7E632803-19F6-4439-AC34-C805DADF4249 Q34557706-463015FF-C458-4C7A-B543-05C9200C4798 Q35089398-CF89C703-2B12-4344-85B4-F668CF1CDCF8 Q35199186-C6A8375C-3EEB-48C2-A4E1-A4EE7873A64B Q35538532-34488107-F0FF-496C-86EA-1643859BC1C6 Q35580361-5C839625-18AB-4E8A-9EFE-26C16BFC4E7A Q35646906-A4631F14-68D6-4B11-9D2B-776995FF74DE Q35749186-3A5D7462-E0C1-4006-B146-50F658004C19 Q36064491-D98E4147-24DE-4CE4-8C4A-18DD5735642D Q36388893-E742D99A-1F00-4995-BB65-C6D72433298E Q36703335-336DA8E6-F0AB-481C-A0C6-CC85E16E0700 Q36799026-EC3F1E34-7CB0-4867-A84E-FC420EF93AC9 Q36802786-B8A973A4-C230-4B2C-9754-7C4B72B91E65 Q36812599-F0BDA051-95AD-47FE-80C4-C8826AA9972D Q37376724-A96BDB78-2CC2-46B2-A489-6A1F7CF43337 Q37490388-5FB301B4-61A1-40C6-B449-8AC1DDDB3F6A Q37668009-58AF9A69-D580-4B18-A0FC-C62BF81D3E68 Q38128733-318EA9CA-E3B6-427C-8E51-7BE0D339331B Q38176164-660921F8-9873-4520-8478-284863CB5EDC Q38574831-FE1B8CB2-E20E-4F5C-BF8F-FEAA73F1A893 Q38650284-52E1BBAA-C00F-4BE9-A70D-FFDB3B3529D6 Q38853682-66FFF03A-51C0-4B7A-88BA-74CD2C87FE22 Q38990885-4B923E74-3558-4C88-952B-E657F6A0324F Q39305705-780C484F-D1CA-4AD4-BE6C-A43112916D6A Q40385925-868A68B1-7A50-4CE8-81B3-F6DAEFED7D26 Q44141796-DDB0D6D9-2D06-47FC-9FB9-412A56E02307 Q47251080-C5575E76-E023-4430-9FAF-B88E3F8AEFD6 Q47636416-4A502421-DF9A-4FB9-8207-58FADBD9FFB1

P2860

Antidepressant effects of the muscarinic cholinergic receptor antagonist scopolamine: a review

http://www.wikidata.org/entity/Q26822244

description

2013 nî lūn-bûn

@nan

2013 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Antidepressant effects of the ...... tagonist scopolamine: a review

@ast

Antidepressant effects of the ...... tagonist scopolamine: a review

@en

Antidepressant effects of the ...... tagonist scopolamine: a review

@nl

type

label

Antidepressant effects of the ...... tagonist scopolamine: a review

@ast

Antidepressant effects of the ...... tagonist scopolamine: a review

@en

Antidepressant effects of the ...... tagonist scopolamine: a review

@nl

prefLabel

Antidepressant effects of the ...... tagonist scopolamine: a review

@ast

Antidepressant effects of the ...... tagonist scopolamine: a review

@en

Antidepressant effects of the ...... tagonist scopolamine: a review

@nl

P1433

Q26822244-E18E6882-A5A5-4954-8163-0534C76A9108

P1476

Q26822244-8A2095E2-4496-4933-9725-2F40FED1309D

P2093

Q26822244-481754B9-2529-4DF1-ACA6-2C5241F048F3

P2860

Q26822244-071073A7-669F-43D5-A35D-ABF807201549

Q26822244-0C25C2DA-CB83-435A-8C16-F339D2F777E7

Q26822244-139F00EF-2870-4755-B997-BCCE29D7FE7B

Q26822244-13DA700C-2029-49B9-90C9-6431F882435E

Q26822244-1EB25CA9-98AF-4297-991B-7C7B6C2CF903

Q26822244-2442F7F2-DC2F-4258-AFAC-F1605D68F94A

Q26822244-2A010A78-0FAD-466A-A649-D7136D3B09AD

Q26822244-2D26B0A5-0D48-4A09-BA5D-AEEF55BAB778

Q26822244-2E3E0BAA-5FCA-4E53-928E-D98F5E77177B

Q26822244-2E7FEDAA-33FE-4CCC-9B62-8C47146869A7

P304

Q26822244-282E6E4E-4CAC-46C2-B342-FC8A6C3F08F0

P31

Q26822244-C8D99E6E-D582-4BB0-9B6D-4E3ED8B6AC0A

Q26822244-c03a1638-c41a-451f-b5f2-aa0ec10b7af8

P3181

Q26822244-F02ABA6F-0260-415F-8C7A-9F5C814AAA5B

P356

Q26822244-2F2B0EA9-354F-4CCE-8371-0851691688A2

P407

Q26822244-7CD9C427-1C92-4E8D-9015-39499854E903

P433

Q26822244-578D417D-CE31-48B2-A1BF-335D70AF100C

P478

Q26822244-D21BE948-B4AF-4320-B80D-B7004305D3B3

P50

Q26822244-3548993E-7FC3-4198-A839-DF68A64FCF44

Q26822244-7408855D-F669-4495-AD78-1AA977D73512

P577

Q26822244-50EC7DAE-E253-4ACC-B3A4-49E68B76837A

P698

Q26822244-0EF4E311-B462-49C0-A719-D640E7DB118B

P921

Q26822244-a97b594a-46c4-3ad2-7863-cb9c2ea6750f

P932

Q26822244-9B525DB8-4EE3-48FE-AFA0-E69B377A4165

P3181

P356

J.BIOPSYCH.2012.09.031

P1433

Biological Psychiatry

P1476

Antidepressant effects of the ...... tagonist scopolamine: a review

@en

P2093

Carlos A. Zarate

http://www.w3.org/2001/XMLSchema#string

P2860

Therapeutic use of sleep deprivation in depression

Binding of antidepressants to human brain receptors: focus on newer generation compounds

In vivo muscarinic cholinergic receptor imaging in human brain with [11C]scopolamine and positron emission tomography

Antidepressant effects of ketamine in depressed patients

A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression

mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists

[Muscarinic receptors modulate the mRNA expression of NMDA receptors in brainstem and the release of glutamate in periaqueductal grey during morphine withdrawal in rats].

Scopolamine bioavailability in combined oral and transdermal delivery.

Pharmacokinetic-pharmacodynamic modeling of the electroencephalogram effects of scopolamine in healthy volunteers.

Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors.

P304

1156-63

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

2378004

http://www.w3.org/2001/XMLSchema#string

P356

10.1016/J.BIOPSYCH.2012.09.031

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

73

http://www.w3.org/2001/XMLSchema#string

P50

Wayne C. Drevets

P577

2013-06-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23200525

http://www.w3.org/2001/XMLSchema#string

P921

P932

4131859

http://www.w3.org/2001/XMLSchema#string